<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00267514</url>
  </required_header>
  <id_info>
    <org_study_id>SVCARB00205</org_study_id>
    <nct_id>NCT00267514</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients</brief_title>
  <official_title>A Randomized, Cross-over Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets Dosed Three Times Per Day in Haemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if sevelamer carbonate powder is an effective&#xD;
      treatment for the control of serum phosphorous levels in patients on dialysis when compared&#xD;
      to sevelamer hydrochloride tablets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate the equivalence of sevelamer carbonate powder to sevelamer hydrochloride tablets dosed three times per day (TID) with meals on the control of serum phosphorus levels</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of sevelamer carbonate powder compared to sevelamer hydrochloride tablets dosed TID with meals</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effects of sevelamer carbonate powder to sevelamer hydrochloride tablets when dosed three times a day with meals on: serum calcium-phosphorus product</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipid profile (total cholesterol, high density lipoprotein [HDL] and low density lipoprotein [LDL] and triglycerides)</measure>
    <time_frame>Up to 13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)</intervention_name>
    <description>sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)</intervention_name>
    <description>sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving three times per week haemodialysis for three months or longer.&#xD;
&#xD;
          -  Taking sevelamer hydrochloride alone (e.g. not using other types of phosphate binders&#xD;
             concomitantly) or on combination therapy (e.g. using sevelamer hydrochloride and&#xD;
             calcium containing, or metal phosphate binders concomitantly) not exceeding a total&#xD;
             daily binder dose of 14.4 g, for at least 60 days prior to screening.&#xD;
&#xD;
          -  Have the following documented local laboratory measurements:&#xD;
&#xD;
               1. Two most recent consecutive serum phosphorus measurements that are ≥ 3.0 and ≤&#xD;
                  7.0 mg/dL (≥ 0.96 and ≤ 2.26 mmol/L) within 60 days of screening&#xD;
&#xD;
               2. An most recent iPTH measurement ≤ 900 pg/mL (&lt; 99 pmol/L) within 90 days of&#xD;
                  screening&#xD;
&#xD;
               3. A most recent serum calcium (adjusted for albumin) measurement within normal&#xD;
                  range defined by the local laboratory within 60 days of screening&#xD;
&#xD;
          -  Have the following central laboratory measurements:&#xD;
&#xD;
               1. A serum phosphorus measurement ≥ 5.5 mg/dL (≥ 1.76 mmol/L) at Visit 2 (after&#xD;
                  Washout)&#xD;
&#xD;
               2. A serum iPTH measurement ≤ 800 pg/mL at Visit 5 (prior to randomization)&#xD;
&#xD;
               3. A serum phosphorus measurement ≥ 3.0 and ≤ 6.5 mg/dL (≥ 0.96 and ≤ 2.08 mmol/L)&#xD;
                  at Visit 5&#xD;
&#xD;
          -  If on vitamin D replacement or calcimimetics therapy, be at a stable dose for at least&#xD;
             one month prior to screening and willing to maintain the same dose throughout the&#xD;
             duration of the study, except for safety reasons.&#xD;
&#xD;
          -  Willing to maintain screening doses of lipid medication for the duration of the study,&#xD;
             except for safety reasons.&#xD;
&#xD;
          -  Willing to avoid any intentional changes in diet such as fasting or dieting.&#xD;
&#xD;
          -  If female and of childbearing potential (pre-menopausal and not surgically sterile),&#xD;
             willing to use an effective contraceptive method throughout study, which includes&#xD;
             barrier methods, hormones, or intrauterine devices (IUDs).&#xD;
&#xD;
          -  Willing to stop all calcium supplements not prescribed by the investigator including&#xD;
             multivitamins containing calcium.&#xD;
&#xD;
          -  Willing to refrain from using aluminium, calcium, lanthanum, or magnesium containing&#xD;
             antacids throughout duration of the study unless prescribed by the investigator as a&#xD;
             calcium supplement per protocol.&#xD;
&#xD;
          -  Have a level of understanding and willingness to cooperate with all visits and&#xD;
             procedures, including telephone contacts, as described in the consent by the study&#xD;
             site personnel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have poorly controlled diabetes mellitus or hypertension, active vasculitis, HIV&#xD;
             infection, or any clinically significant unstable medical condition (defined by&#xD;
             investigator).&#xD;
&#xD;
          -  Have active dysphagia, swallowing disorders, bowel obstruction, or severe&#xD;
             gastrointestinal motility disorders.&#xD;
&#xD;
          -  Have participated in a study of an investigational drug during the 30 days preceding&#xD;
             the start of the screening period.&#xD;
&#xD;
          -  Has active ethanol or drug dependence or abuse, excluding tobacco use.&#xD;
&#xD;
          -  Have any other condition, which, in the investigator's opinion, will prohibit the&#xD;
             patient's participation in the study.&#xD;
&#xD;
          -  If female, be pregnant or breast-feeding.&#xD;
&#xD;
          -  Have any evidence of active malignancy except for basal cell carcinoma of the skin. A&#xD;
             history of malignancy is not an exclusion.&#xD;
&#xD;
          -  Use of anti-arrhythmic or anti-seizure medications for arrhythmia or seizure&#xD;
             disorders.&#xD;
&#xD;
          -  Have a known hypersensitivity to sevelamer or any of its constituents.&#xD;
&#xD;
          -  Have a poor record of compliance with medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southmead Hospital</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooks NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>December 20, 2005</study_first_submitted>
  <study_first_submitted_qc>December 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2005</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <name_title>Medical Monitor</name_title>
    <organization>Genzyme Corporation</organization>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

